Drugs / IMG-007
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06304740 | Mar → Aug 2024 | — | Inmagene LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05353972 | Jul 2022 → May 2023 | — | Inmagene LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06060977 | Sep 2023 → Jan 2025 | alopecia areata | Inmagene LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT05984784 | Aug 2023 → Apr 2024 | atopic eczema | Inmagene LLC | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07037901 | Jun 2025 → Dec 2027 expected | atopic eczema | Inmagene LLC | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-06 | Hutchison Medipharma Limited | Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 hutch-med.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMG-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05984784 ↗ |
| Route | Intravenous | “intravenously administered” NCT05353972 ↗ |